Sarpogrelate Use and Clinical Outcomes After Drug-Eluting Stent in Patients With Diabetes Mellitus(s-code), a Single Center Trial

Introduction: Diabetes mellitus (DM) still remains a strong risk factor for the early restenosis and target lesion revascularization (TLR) after implanting drug-eluting stent (DES). 5-Hydroxytryptamine (5-HT) is known to induce platelet aggregation, proliferation of vascular smooth muscle cells and vasoconstriction. Sarpogrelate is the selective 5-HT2A receptor antagonist, which has been used clinically to prevent atherosclerosis. Hypothesis: We assessed the hypothesis that adding sarpogrelate with standard dual antiplatelet therapy (DAPT) would lower restenosis after DES implantation in the CAD patients with DM or impaired glucose tolerance (IGT). Methods: We undertook a prospective, open-label randomized trial in 148 patients with DM or IGT, who were planned for elective percutaneous coronary intervention (PCI) using DES for de-novo native coronary artery lesions. Patients were assigned to receive standard DAPT (aspirin 100mg daily and clopidogrel 75mg daily or ticlopidine 200mg daily) or sarpogrelate 3...